

[Trouble viewing email, click here](#)




March 2017

Share:



cell passages



Visit us at AACR Annual Meeting 2017

Are you going to the AACR Annual Meeting 2017? Stop by booth #1717 and learn about ATCC's broad range of cancer research tools:

- Angiogenesis cells and assay
- Isogenic cell lines
- Primary cells and hTERT-immortalized primary cells
- Quantitated genomic cell line DNA
- Tumor cell panels
- Cell lines for cancer screening applications
- K-562-GFP cells for cancer immunology studies

[Discover ATCC Cancer Research Resources](#)

If you're going to AACR, don't miss our scientific poster presentations:



Development of a high-throughput, cell-based, co-culture angiogenesis assay system using hTERT-immortalized cells

Chaozhong Zou, Ph.D., *Senior Scientist*, ATCC

April 2, 1:00 - 5:00 PM, Halls A-C, Poster Section 37

Board #19, Abstract #792



A new type of drug resistant isogenic cancer cell model created by CRISPR genome editing

Fang Tian, Ph.D., *Lead Scientist*, ATCC

April 4, 8:00 AM - 12:00 PM, Halls A-C, Poster Section 37


Board #2, Abstract #3836

Characterization of hTERT-immortalized prostate-derived stromal and epithelial cells: An authentic *in vitro* model for tumor microenvironment studies



Luis Rodriguez, Ph.D., *Scientist*, ATCC

April 4, 1:00 - 5:00 PM, Halls A-C, Poster Section 44
Board #30, Abstract #4948



NRAS Mutant Isogenic Cells

ATCC has recently employed CRISPR/Cas9 gene editing to create the NRAS Mutant A375 Isogenic Cell Line ([ATCC® CRL-1619IG-2™](#)), which contains the NRAS Q61K mutation. Used with the parental A375 ([ATCC® CRL-1619™](#)) cell line as a control, the NRAS Mutant A375 Isogenic Cell Line is the ideal model for the study of BRAF inhibitor resistance and an excellent tool for cancer therapy development.

[Order ATCC Isogenic Cell Lines.](#)



Webinar: New Isogenic Cell Models

Created by CRISPR Genome Editing for Drug Discovery

Presenters:

Fang Tian, Ph.D. & Lysa-Anne Volpe, M.S.
April 13, 12:00 ET

In this webinar, ATCC scientists will address the current role of CRISPR/Cas9 in drug discovery. Dr. Tian and Ms. Volpe will present how ATCC utilized this advanced technology to create novel human cell models that contain disease-relevant point mutations and gene rearrangements. In addition, they will introduce a new drug resistant cell line that was created using CRISPR/Cas9.

[Register for this webinar.](#)



NIST DNA Standards

ATCC offers DNA standards from the National Institute of Science and Technology (NIST). These DNA standards are intended for assessing performance of human genome sequencing, including whole genome sequencing, whole exome sequencing, or more targeted sequencing such as gene panels.

Ideal for procedures such as:

- Biomarker evaluation
- Forensics
- Paternity testing



Biorepository Services

Biorepository Services ATCC is proud to introduce our new state-of-the-art biorepository in Gaithersburg, MD, which opens in April 2017. With ATCC Biorepository Services, you can expect:

- cGMP compliant and non-cGMP storage options
- Temperature-controlled supply chain
- 24/7 equipment monitoring
- On-call after-hours personnel
- Flexible storage choices!


With over 90 years of experience focused

Quality assurance

[Order NIST DNA Standards.](#)

solely on biomaterial services and management, ATCC has the expertise to store and distribute your biological materials worldwide.

[Explore our biorepository service today!](#)



ATCC Puzzle

Try this [month's crossword puzzle](#) and test your knowledge of gene editing. The solution will appear in next month's issue.

For the solution to last month's Toxic Trials puzzle [click here](#).

Resources

- [Isogenic Cell Lines](#)
- [The Generation of an EML4-ALK Fusion NSCLC Isogenic Cell Line Relevant for Drug Discovery and Development](#)
- [Cancer Resources](#)
- [Cell Line Genomic DNA](#)



Frequently Asked Questions

Q: What are the advantages of NRAS mutant-A375 Isogenic Cell Line ([ATCC® CRL-1619IG-2™](#)) as a melanoma model?

A: B-Raf V600E mutation occurs in approximately 40% to 50% of melanomas. Although current B-Raf inhibitors have been used as therapeutics to treat melanomas, patients often become resistant to the drugs several months after treatment. One mechanism of resistance to these inhibitors is caused by an acquired secondary NRAS Q61K mutation.

CRL-1619IG-2 is an isogenic cell line generated at ATCC by using the CRISPR/Cas9 gene editing technology to generate a drug resistant NRAS Q61K mutation in the A-375 ([ATCC® CRL-1619™](#)) melanoma cell line, which naturally harbors the B-Raf V600E mutation. [ATCC® CRL-1619IG-2™](#) can be a useful model to study B-Raf drug resistance, RAS–RAF–MEK–ERK–MAP kinase signaling pathway, and to screen next generation B-Raf inhibitors and anti-cancer compounds that can overcome drug resistance in drug discovery and development.

[Have more questions?](#)

[Cell Biology Collections](#)

[Cell Line Authentication](#)

[Facebook](#)

[Cell Biology Resources](#)

[Webinar Registration](#)

ATCC - 10801 University Boulevard, Manassas, VA 20110

© 2017 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise. ToxExpo™ is a trademark of the Society of Toxicology.

To receive emails from ATCC, please take a few minutes to update your profile [click here](#).

To Unsubscribe, click [here](#).

[Privacy Policy](#).